VCYTClinical Trials•businesswire•
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
Sentiment:Positive (70)
Summary
(NASDAQ:VCYT) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking place September 10-14 at the Westin Kierland in Scottsdale, Ariz. The large number of abstracts stems from Veracyte’s extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles—which is the largest dataset of its kind in thyroid c
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2025 by businesswire